BOREAS事后分析:2型炎症生物标志物与度普利尤单抗治疗慢阻肺的应答关联
BOREAS是一项3期随机对照试验的事后分析,纳入939例伴2型炎症的慢阻肺患者,比较度普利尤单抗300mg每2周与安慰剂治疗52周。结果显示度普利尤单抗组多数2型炎症生物标志物中位下降幅度大于安慰剂组,且基线血嗜酸性粒细胞计数和FeNO较高者急性加重风险下降更明显。
要点
- 度普利尤单抗可降低慢阻肺患者2型炎症生物标志物水平。
- 基线血嗜酸性粒细胞计数较高者急性加重风险下降更明显(p=0·0056)。
- 基线FeNO较高者急性加重风险下降更明显(p=0·043)。
核心结论
- 伴2型炎症的慢阻肺患者接受度普利尤单抗后2型炎症生物标志物降低,血嗜酸性粒细胞计数和FeNO升高可预测更好的治疗应答。
研究设计与样本
- BOREAS为3期多中心双盲随机对照试验,在24个国家275个中心开展,纳入筛选时血嗜酸性粒细胞≥300 cells per μL的慢阻肺患者939例,按1:1随机分配接受度普利尤单抗300 mg每2周或安慰剂治疗52周。
- 本分析为事后分析,在安全性人群中评估血嗜酸性粒细胞计数、FeNO、血清eotaxin-3、总血浆IgE及血清PARC浓度。
主要发现
- 第52周时,度普利尤单抗组相较安慰剂组多数生物标志物中位下降百分比更大:总IgE -22·5%(IQR -30·4 to -16·5)vs -0·9%(-6·5 to 4·8);FeNO -28·6%(-57·1 to 0)vs -6·9%(-35·7 to 25·0);eotaxin-3 -8·8%(-15·6 to -2·9)vs -0·4%(-5·6 to 5·0);PARC -14·4%(-29·2 to 2·1)vs -0·8%(-13·9 to 17·2)。
- 按血嗜酸性粒细胞计数分层,各治疗组间下降幅度相似。
- 总体急性加重风险降低,基线血嗜酸性粒细胞计数较高者下降幅度更大(p=0·0056),基线FeNO较高者下降幅度也更大(p=0·043)。
临床怎么用
- 对伴2型炎症的慢阻肺患者,可考虑检测基线血嗜酸性粒细胞计数和FeNO以识别更可能从度普利尤单抗治疗中获益的人群。
局限性
- 本分析为BOREAS试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A raised blood eosinophil count (≥300 cells per μL), a marker of type 2 inflammation, can identify patients with chronic obstructive pulmonary disease (COPD) with higher exacerbation risk. Dupilumab reduced exacerbations in patients with COPD and type 2 inflammation in the BOREAS trial. In this post-hoc analysis, we evaluated the predictive value and longitudinal changes in type 2 inflammatory biomarkers in patients with COPD and type 2 inflammation from the BOREAS trial who received dupilumab treatment. METHODS: BOREAS, a phase 3, multicentre, double-blind, randomised trial was conducted at 275 sites in 24 countries and included patients with COPD and type 2 inflammation (screening blood eosinophils ≥300 cells per μL). Patients were randomly assigned (1:1) to receive 300 mg of dupilumab every 2 weeks for 52 weeks or matching placebo. Randomisation was stratified by country and inhaled corticosteroid dose at baseline. This post-hoc analysis assessed blood eosinophil counts, fractional exhaled nitric oxide (FeNO), serum eotaxin-3, total plasma immunoglobulin E (IgE), and serum pulmonary and activation-regulated chemokine (PARC) concentrations in the safety population. The study was registered at ClinicalTrials.gov, NCT03930732 and is complete. FINDINGS: BOREAS was conducted between April 15, 2019, and May 2, 2023, and included 939 patients with COPD and type 2 inflammation. 468 patients were randomly assigned to receive 300 mg of dupilumab every 2 weeks for 52 weeks and 471 were randomly assigned to receive matching placebo. 319 (34%) participants were female and 620 (66%) were male. 657 (70%) were former smokers and 282 (30%) were current smokers. At week 52, greater median percentage reductions were observed in dupilumab versus placebo for most biomarkers (total IgE: -22·5% [IQR -30·4 to -16·5] vs -0·9% [-6·5 to 4·8]; FeNO: -28·6% [-57·1 to 0] vs -6·9% [-35·7 to 25·0]; eotaxin-3: -8·8% [-15·6 to -2·9] vs -0·4% [-5·6 to 5·0]; and PARC: -14·4% [-29·2 to 2·1] vs -0·8% [-13·9 to 17·2]). Reductions were similar across treatment groups by blood eosinophil counts. Exacerbation risk overall was reduced, with a greater magnitude of reduction in those with higher baseline blood eosinophil count (p=0·0056) and baseline FeNO (p=0·043). INTERPRETATION: Patients with COPD and type 2 inflammation who were given dupilumab showed reduced type 2 inflammatory biomarkers, with elevated blood eosinophil count and FeNO predicting greater treatment response. These findings support biomarker-driven treatment strategies to optimise therapy. FUNDING: Sanofi and Regeneron Pharmaceuticals.
引用
- Christenson, Hanania, Bhatt, et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025. PMID: 40651490. doi:10.1016/S2213-2600(25)00044-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。